Company profile
GlucoTrack, Inc.
NASDAQ: GCTK · Healthcare · Medical - Instruments & Supplies
PublicHQ Rutherford, CIK 0001506983Reports USD
#1004 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
28DFH 17DQ 33GM 45SS 40
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), listing tenure · ↓ return on equity, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$19.4M
Employees
15
as of 2026-07-19
Market cap
$263.1k
as of 2026-07-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$208.8k$208.8k2019
Net income-$19.4M-$19.4M2025
Operating income-$16.1M-$16.1M2025
Total assets$7.8M$7.8M2025
Liabilities$5.0M$5.0M2025
Equity$2.8M$2.8M2025
Revenue trend
FY2014 – FY2019 · USD
FY14
FY15
FY16
FY18
FY18
FY19
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is GlucoTrack, Inc.’s revenue?
GlucoTrack, Inc. booked $208.8k in FY2019 revenue, growing 380% year over year — faster than 93% of Healthcare companies we track, at a -9287.1% net margin.
Peers · Healthcare
HAVN Life Sciences Inc.——Brain Scientific Inc.——Anixa Biosciences, Inc.52DSharps Technology, Inc.33DLixte Biotechnology Holdings, Inc.40DClene Inc.27DKey facts
CEOPaul V. Goode
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersRutherford, null
ExchangeNASDAQ: GCTK
Employees15
IPO date2013-04-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.